Biofil Chemicals & Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 |
|---|---|---|---|
| Sales | 8 Cr | 6 Cr | 14 Cr |
| Operating expenses (approx.) | 8 Cr | 4 Cr | 13 Cr |
| EBITDA | 0.34 Cr | 3 Cr | 0.18 Cr |
| OPM % | 4.1% | 44.1% | 1.3% |
| Other income | 0.24 Cr | 3 Cr | 0.06 Cr |
| Interest | 0.0075 Cr | 0.0093 Cr | 0.0001 Cr |
| Depreciation | 0.08 Cr | 0.07 Cr | 0.07 Cr |
| Profit before tax | 0.25 Cr | 3 Cr | 0.11 Cr |
| Tax % | 21.4% | 12.7% | 25.2% |
| Net profit | 0.20 Cr | 2 Cr | 0.08 Cr |
| EPS (₹) | ₹0.12 | ₹1.48 | ₹0.05 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 33 Cr | Sign in for TTM |
| Operating expenses (approx.) | 32 Cr | Sign in for TTM |
| EBITDA | 1 Cr | Sign in for TTM |
| OPM % | 3.5% | Sign in for TTM |
| Other income | 0.31 Cr | Sign in for TTM |
| Interest | 0.04 Cr | Sign in for TTM |
| Depreciation | 0.38 Cr | Sign in for TTM |
| Profit before tax | 0.74 Cr | Sign in for TTM |
| Tax % | 24.2% | Sign in for TTM |
| Net profit | 0.56 Cr | Sign in for TTM |
| EPS (₹) | ₹0.34 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 16 Cr |
| Reserves | 3 Cr |
| Borrowings | 0.47 Cr |
| Other liabilities | 32 Cr |
| Total liabilities | 51 Cr |
| Fixed assets (net) | 8 Cr |
| CWIP | — |
| Investments | 0.0000 Cr |
| Other assets | 43 Cr |
| Total assets | 51 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | -2 Cr |
| Cash from investing | -0.10 Cr |
| Cash from financing | -0.0045 Cr |
| Net cash flow | -2 Cr |
| Free cash flow (OCF − Capex) | -2 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 4.0% |
| ROE % | 3.0% |
| Debtor days | — |
| Inventory days | 229 |
| Days payable | — |
| Cash conversion cycle | 229 |
| Debt / equity | 0.03 |
| Current ratio | 1.34 |
| Net debt / EBITDA | 0.29 |
Compare with peers
Loading peers…